Urogenit Tract Infect.  2019 Aug;14(2):42-45. 10.14777/uti.2019.14.2.42.

Risk Factor Associated with Recurrence after OM-89 (Uro-Vaxom®) Treatment for Female Recurrent Cystitis

Affiliations
  • 1Department of Urology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Busan, Korea. jyincomo@gmail.com

Abstract

PURPOSE
This study evaluated the risk factors associated with recurrence OM-89 (Uro-Vaxom®) treatment for female recurrent cystitis.
MATERIALS AND METHODS
The medical records of patients who received OM-89 for at least six months were reviewed retrospectively. Patients were excluded from the analysis if they had an abnormal lower urinary tract anatomy, residual urine volume ≥200 ml, a history of genitourinary tuberculosis, urological cancer or pelvic radiation, indwelling urinary catheter, or had genitourinary surgery within the previous six months. Patients were categorized into two groups: (1) no recurrence and (2) recurrent cystitis after OM-89. The risk factors in the two groups were compared. The recurrent cystitis was defined as two more infections in six months or three or more in one year.
RESULTS
A total of 52 female were included. Group 1 had 35 (67.3%) patients and group 2 had 17 (32.7%) patients. Before and after the OM-89, the mean cystitis episodes for six months of groups 1 and 2 were 4.19±4.60 (range, 2-24) and 1.17±1.79 (range, 0-6), respectively, which were decreased significantly (p <0.001). For recurrence after the OM-89, the only risk factor was uncontrolled diabetes (fasting plasma glucose level >120 mg/dl±casual plasma glucose >180 mg/dl) (p=0.002). No significant differences in the age, menopause, daily water intake, hormone replacement therapy or history of extended-spectrum beta-lactamase-producing Escherichia coli were observed between the two groups.
CONCLUSIONS
OM-89 was effective in the management of recurrent cystitis in female. On the other hand, uncontrolled diabetes was a risk factor for treatment failure of OM-89.

Keyword

Cystitis; Diabetes mellitus; Immunotherapy; Recurrence

MeSH Terms

Blood Glucose
Cystitis*
Diabetes Mellitus
Drinking
Escherichia coli
Female*
Hand
Hormone Replacement Therapy
Humans
Immunotherapy
Medical Records
Menopause
Recurrence*
Retrospective Studies
Risk Factors*
Treatment Failure
Tuberculosis
Urinary Catheters
Urinary Tract
Urologic Neoplasms
Full Text Links
  • UTI
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error